Cases & Deals

Merck asserts patent infringement claims under Hatch-Waxman Act relating to Bridion® against 16 generic drug makers

Clients Merck & Co., Inc.

Jones Day is representing Merck & Co., Inc. in Hatch-Waxman patent infringement actions against 16 generic drug maker defendant groups, relating to the defendant groups' submissions of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of Bridion®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.

In re Sugammadex, No. 2-20-cv-02576 (CCC) (MF) (consolidated) (D.N.J.)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.